首页> 外文期刊>Acta Cirurgica Brasileira >Ki-67 expression score correlates to survival rate in gastrointestinal stromal tumors (GIST)
【24h】

Ki-67 expression score correlates to survival rate in gastrointestinal stromal tumors (GIST)

机译:Ki-67表达评分与胃肠道间质瘤(GIST)的存活率相关

获取原文
           

摘要

PURPOSE: To evaluate the immunohistochemical expression of p16, Ki-67, p53 and Bcl-2 proteins in gastrointestinal stromal tumors (GIST); to assess the possible association between these variables and clinical and histopathological factors of cancer; and to check for prognostic value of these variables (survival and recurrence). METHODS: A sample of 55 patients treated surgically for GIST in three hospitals was studied. The surgically excised tumors were confirmed as GIST by KIT, vimentin, desmin S100 protein, CD117, 1A4 and CD34 assessment in paraffin blocks. RESULTS: Only 9 (16%) cases of GIST were positive for p53, p16 was positive among 43.6%; 80% of GISTs showed staining for Bcl-2. The proliferative index (expressed as the proportion of positive cells) assessed by immunohistochemical expression of Ki-67 was high in 49% of cases. Elevated Ki-67 scores were associated to high histological grade (p=0.0026) and mitosis index, MI (p=0.0001). High Ki-67 index was associated to death. Expression of p53, p16 and Bcl-2 did not correlate to morphological or clinical variables. CONCLUSIONS: Ki-67 immunohistochemical evaluation should be included in preoperative evaluation of GIST biopsies or surgical specimens as a prognostic tool for clinical staging; and all other proteins studied (Bcl-2, p53 and p16) did not play a role in GIST metabolic or carcinogenic process, remaining without prognostic value.
机译:目的:评估p16,Ki-67,p53和Bcl-2蛋白在胃肠道间质瘤(GIST)中的免疫组化表达;评估这些变量与癌症的临床和组织病理学因素之间的可能联系;并检查这些变量(生存和复发)的预后价值。方法:对三所医院接受GIST手术治疗的55例患者进行了研究。手术切除的肿瘤通过石蜡块中的KIT,波形蛋白,结蛋白S100蛋白,CD117、1A4和CD34评估确认为GIST。结果:仅9例(16%)GIST的p53阳性,p16阳性的占43.6%; 80%的GIST显示Bcl-2染色。通过Ki-67免疫组织化学表达评估的增殖指数(以阳性细胞的比例表示)在49%的病例中较高。 Ki-67评分升高与较高的组织学等级(p = 0.0026)和有丝分裂指数MI(p = 0.0001)相关。 Ki-67指数高与死亡有关。 p53,p16和Bcl-2的表达与形态或临床变量无关。结论:GIST活检或手术标本的术前评估应包括Ki-67免疫组织化学评估,作为临床分期的预后工具。以及其他所有研究的蛋白质(Bcl-2,p53和p16)在GIST代谢或致癌过程中均未发挥作用,但仍无预后价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号